Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="54656" type="General" weightage="20" keywordseo="indian-embassy" source="Orion">Indian Embassy</keyword> in Rome said on Friday that the country has recognised the <keyword id="9617748" type="General" weightage="100" keywordseo="covishield" source="Orion">Covishield</keyword> vaccine and people who have received the jab are now eligible for a <keyword id="9276440" type="General" weightage="80" keywordseo="green-pass" source="Orion">Green Pass</keyword>. With <keyword id="21474" type="General" weightage="80" keywordseo="italy" source="Orion">Italy</keyword>'s recognition, a total 19 European Union (EU) nations have given their go-ahead to Covishield. This is the outcome of a G20 Health Ministers meeting between Union Health Minister <keyword id="2607815" type="General" weightage="20" keywordseo="mansukh-mandaviya" source="Orion">Mansukh Mandaviya</keyword> and his Italian counterpart Roberto Speranza, the Embassy said in a tweet. "Indian vaccine CardHolders are now eligible for the Green Pass," it added Prior to this, Italy had recognised Comirnaty - Pfizer, Moderna, Vaxzervria - AstraZeneca, and <keyword id="92247" type="General" weightage="20" keywordseo="johnson-johnson" source="Orion">Johnson &amp; Johnson</keyword> vaccines as valid. The other 18 EU nations that have recognised the Covishield vaccine are Austria, Belgium, Bulgaria, Croatia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Netherlands, Romania, Slovenia, Spain, Sweden, and Switzerland. Meanwhile, the vaccine row with the UK continues as it has recognised the jab but a 10-day quarantine has been made mandatory which will come into the effect from October 4. Terming the present UK travel restrictions as discrimatory, Union Health Secretary Rajesh Bhushan said that "we have the right to reciprocate in the same manner". However, the British High Commissioner to India Alex Ellis said that Covishield vaccine is not a problem and the UK is open to travel. "We're clear Covishield is not a problem. The UK is open to travel and we're already seeing a lot of people going from India to the UK, be it tourists, business people or students". SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/environment/news/heres-how-researchers-are-considering-fly-ash-recycled-phones-and-slag-to-lower-global-carbon-emissions-from-cement/articleshow/86477965.cms">Here’s how researchers are considering fly ash, recycled phones and slag to lower global carbon emissions from cement</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/bharat-bandh-called-by-dmk-on-september-27-to-protect-the-rights-of-the-farming-community/articleshow/86474697.cms">Bharat Bandh called by DMK on September 27 to 'protect the rights of the farming community'</a>

After UK and US, Italy also gives green pass to Covishield vaccine

India's drug regulator has given approval for a study to be conducted by the <keyword id="93589" type="ORGANIZATION" weightage="20" keywordseo="Christian-Medical-College">Christian Medical College</keyword> (CMC), Vellore on mixing of COVID-19 vaccines <keyword id="9485939" type="LOCATION" weightage="20" keywordseo="covaxin">Covaxin</keyword> and Covishield, official sources said on Wednesday. An expert panel of the <keyword id="170943" type="ORGANIZATION" weightage="20" keywordseo="Central-Drugs-Standard-Control-Organisation">Central Drugs Standard Control Organisation</keyword> (CDSCO) on July 29 had recommended granting permission for conducting the study. The trial will involve 300 healthy volunteers. "The aim of the study is to assess the feasibility on whether a person can be given two different vaccine shots -- one each of Covishield and Covaxin -- to complete the inoculation course," a source said. Separately, a recent study by the Indian Council of Medical Research (ICMR) involving 98 people, 18 of whom had inadvertently received Covishield as the first dose and Covaxin as the second in <keyword id="413944" type="PERSON" weightage="20" keywordseo="uttar">Uttar</keyword> Pradesh, showed that combining these two COVID-19 vaccines elicited better immunogenicity than two doses of the same vaccine. The study also found that immunisation with combination of Covishield and Covaxin was safe and the adverse effects were also found to be similar when compared to the same dose regimen. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/mobile/news/xiaomi-launches-mi-mix-4-its-first-under-display-camera-phone/articleshow/85231596.cms">Xiaomi debuts its first under-display camera on the Mi Mix 4</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/mobile/news/oneplus-teases-a-foldable-phone-announcement-clashing-with-samsungs-unpacked-event/articleshow/85233365.cms">OnePlus teases a foldable phone announcement clashing with Samsung’s Unpacked event</a>

DCGI approves study on mixing of Covaxin and Covishield  COVID-19 doses, say sources

<keyword id="9265079" type="COMPANY" weightage="20" keywordseo="the-serum-institute-of-india">The Serum Institute of India</keyword> on Sunday became the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for the Oxford COVID-19 vaccine in the country citing unmet medical needs due to the pandemic and in the interest of the public at large, official sources said. A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek a similar approval from India's drug regulator for its own COVID-19 vaccine in the country, after securing such clearance in the UK and Bahrain. The phase-three clinical trial of the Oxford COVID-19 vaccine, Covishield, is being conducted by the Pune-based Serum Institute of India on Sunday (SII), co-sponsored by <keyword id="6364555" type="COMPANY" weightage="20" keywordseo="Indian-Council-of-Medical-Research">Indian Council of Medical Research</keyword> (ICMR), in various parts of the country in addition to clinical studies being carried out by <keyword id="9605255" type="COMPANY" weightage="20" keywordseo="oxford-astrazeneca">Oxford-AstraZeneca</keyword> in the UK and Brazil. Based on phase two and three clinical trial results, the SII with the help of the ICMR will pursue early availability of the vaccine for India, the country's apex health research body had said last month. According to the ICMR, the SII has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the DCGI. Official sources, citing the SII application, said the firm has stated that data from four clinical studies, two in the UK and one each in Brazil and India, shows that Covishield is highly efficacious against symptomatic and most importantly against severe COVID-19 infections. The results are in line with other anti-coronavirus vaccines and because of the huge disease burden, Covishield is predicted to alleviate substantial COVID-19 mortality and morbidity, the firm is learnt to have said. "In terms of safety, Covishield was well tolerated with respect to solicited adverse events and was not associated with an increased number of SAEs and deaths. A majority of solicited reactions were mild in severity and resolved without any sequelae. "Therefore, Covishield is safe and well-tolerated and can be used effectively for prevention of COVID-19 in the targeted population. Thus, the benefit to risk ratio strongly supports the widespread use of Covishield," a source said quoting the application. In order to introduce an urgently needed vaccine against COVID-19 in India, SII, the world's largest vaccine manufacturer, has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has also submitted 12 batches of the vaccine to <keyword id="9576145" type="COMPANY" weightage="20" keywordseo="the-central-drugs-laboratory">the Central Drugs Laboratory</keyword> (CDL) in Kasauli for testing, a source said. "In line with our philosophy we assure you that for COVID-19 vaccines also, we are committed to make our country 'aatmanirbhar' (self-reliant) and fulfil our prime minister's clarion call of 'vocal for local' and 'making in India' for the world," stated the application signed by Prakash Kumar Singh, Additional Director, <keyword id="2344259" type="COMPANY" weightage="20" keywordseo="Government-and-Regulatory-Affairs">Government and Regulatory Affairs</keyword> at Serum Institute of India (SII). In view of all these facts and unmet medical needs in the interest of the public at large to save millions of people in the country and across the globe, early availability of a vaccine against COVID-19 is a necessity, it stated. "So, in the national interest, we request you to grant us emergency use authorisation of Covishield based on our application and in view of immediate need for a safe, effective, programmatically suitable and affordable vaccine for our country," the application read. According to sources, this vaccine is logistically feasible for distribution in the country's both urban and rural parts as it can be stored at two to eight degrees Celsius, which is an ideal temperature for being kept in cold storages in the country. As a rapid regulatory response, the DCGI on August 2 had given nod to SII for conducting the combined phase two and three human clinical trials of the Oxford COVID-19 vaccine in the country. PLB BJ NSD NSD NSD

Oxford COVID-19 vaccine: Serum Institute seeks emergency use nod for Covishield vaccine in India

<ul class="summary-list"><li>Six fully vaccinated people died of COVID-19 in <keyword id="63095" type="COUNTRY" weightage="60" keywordseo="Seychelles">Seychelles</keyword>, the public-health commissioner said.</li><li>Five had gotten Covishield, a version of <keyword id="6409874" type="COMPANY" weightage="60" keywordseo="astrazeneca">AstraZeneca</keyword>'s shot, and one had gotten <keyword id="522337" type="ORGANIZATION" weightage="60" keywordseo="Sinopharm">Sinopharm</keyword>'s shot.</li><li>All of those who died had underlying health conditions, the commissioner said.</li></ul>Six people have died from COVID-19 in Seychelles despite being fully vaccinated, the country's public-health commissioner said on Thursday.Jude Gedeon said that five of the people had received Covishield, a version of AstraZeneca's COVID-19 vaccine manufactured in India, and that one had received <a href="https://www.businessinsider.com/china-vaccines-questioned-after-virus-surges-countries-using-them-2021-6" target="_blank" rel="noopener">China's Sinopharm</a> shot<a href="https://www.businessinsider.com/china-vaccines-questioned-after-virus-surges-countries-using-them-2021-6" target="_blank" rel="noopener">,</a> <a href="https://www.bloomberg.com/news/articles/2021-07-01/six-fully-vaccinated-people-have-died-of-covid-19-in-seychelles?sref=lAVQtUwz" target="_blank" rel="noopener">Bloomberg reported</a>.All six people had underlying health conditions, he said. It wasn't clear how long after vaccination the people died. In Seychelles, the Covishield shot has mostly been given to people older than 60, Gedeon said.Seychelles is the world leader in vaccination rates, having fully vaccinated 68% of its 98,000 people. For comparison, Israel, a country lauded for its <a href="https://www.businessinsider.com/israel-seeing-new-covid-19-outbreak-despite-vaccine-success-2021-6" target="_blank" rel="noopener">vaccination success</a>, has fully vaccinated 59% of its population, <a href="https://ourworldindata.org/covid-vaccinations">according to Oxford University's Our World in Data</a>. The world average is 11%.Gedeon said that a recent spike in infections had likely been driven by the <a href="https://www.businessinsider.com/fauci-delta-variant-doubled-2-weeks-2021-6" target="_blank" rel="noopener">highly infectious Delta variant</a>, first found in India, that's fast spreading across the world. Before that, <a href="https://www.businessinsider.com/coronavirus-variants-uk-south-africa-brazil-us-facts-questions-2021-1" target="_blank" rel="noopener">the Beta variant</a>, first found in South Africa, was dominant. Both strains have mutations that help the virus escape the antibody response, <a href="https://www.businessinsider.com/quatar-real-world-data-suggests-two-doses-are-needed-against-variants-2021-5" target="_blank" rel="noopener">reducing the effectiveness of vaccines</a>.Other countries with high vaccination rates, such as Israel, have reported <a href="https://www.businessinsider.com/delta-variant-less-deadly-vaccinated-countries-mild-approach-lockdown-covid-2021-6" target="_blank" rel="noopener">a rise in cases driven by the Delta variant but not a sharp rise in deaths</a>.Read more: <a href="https://www.businessinsider.com/vaccine-mrna-covid-drug-treatment-future-of-medicine-2021-5" target="_blank" rel="noopener">Experts explain why the mRNA tech that revolutionized COVID-19 vaccines could be the answer to incurable diseases, heart attacks, and even snake bites: 'The possibilities are endless'</a>The Seychelles Ministry of Health said on May 10 that about a third of active COVID-19 cases were among fully vaccinated people. At the time, most people in the country had received Sinopharm's shot.As of Monday, Seychelles had reported more than 15,000 COVID-19 cases and 68 deaths, <a href="http://www.health.gov.sc/" target="_blank" rel="noopener">according to the ministry's data</a>. It has the highest proportion of newly confirmed infections of any country - on Tuesday, it had a seven-day average of 1,393 new daily <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> cases per million people, while the US's average was 37 new cases, <a href="https://ourworldindata.org/covid-cases" target="_blank" rel="noopener">according to Our World in Data</a>.Seychelles has imposed restrictions on gatherings and opening hours at bars to try to curb the spread of the virus.Gedeon said Seychelles was working with experts from the World Health Organization and the Africa Centers for Disease Control and Prevention to evaluate the country's vaccination rate, data, and response. "They will produce a report which will help us decide on the strategy to be used moving forward in terms of vaccination, measures, etc.," he said, according to Bloomberg.

You Searched For "covishield vaccinated people" and got 4 results

After UK and US, Italy also gives green pass to Covishield vaccine

IANS

DCGI approves study on mixing of Covaxin and Covishield COVID-19 doses, say sources

PTI

Oxford COVID-19 vaccine: Serum Institute seeks emergency use nod for Covishield vaccine in India

PTI

6 fully vaccinated people died of COVID-19 in the world's most vaccinated nation, health officials said. All had underlying health conditions.

Dr. Catherine Schuster-Bruce

Popular Keywords

Buying Guides